RU-22930: Difference between revisions
Content deleted Content added
m Task 18 (cosmetic): eval 3 templates: del empty params (2×); |
m Added UNII |
||
| (2 intermediate revisions by 2 users not shown) | |||
| Line 29: | Line 29: | ||
<!-- Identifiers --> |
<!-- Identifiers --> |
||
| CAS_number_Ref = |
| CAS_number_Ref = {{cascite|correct|CAS}} |
||
| CAS_number = |
| CAS_number = 63094-42-8 |
||
| UNII_Ref = {{fdacite|correct|FDA}} |
|||
| ⚫ | |||
| CAS_supplemental = |
| CAS_supplemental = |
||
| ATC_prefix = |
| ATC_prefix = |
||
| Line 41: | Line 43: | ||
| ChemSpiderID_Ref = |
| ChemSpiderID_Ref = |
||
| ChemSpiderID = 8124041 |
| ChemSpiderID = 8124041 |
||
| ⚫ | |||
| KEGG = |
| KEGG = |
||
| ChEBI = |
| ChEBI = |
||
| ChEMBL = |
| ChEMBL = |
||
| synonyms = 5,6-Dihydro-2-methyl-4-[4-nitro-3-(trifluoromethyl)phenyl]-2''H''-1,2,4-oxadiazin-3-(4''H'')-one<ref name="US4684635">https://www.google.com/patents/US4684635</ref> |
| synonyms = 5,6-Dihydro-2-methyl-4-[4-nitro-3-(trifluoromethyl)phenyl]-2''H''-1,2,4-oxadiazin-3-(4''H'')-one<ref name="US4684635">{{Cite web|url=https://www.google.com/patents/US4684635|title = Compositions and methods for inhibiting the action of androgens}}</ref> |
||
<!--Chemical data--> |
<!--Chemical data--> |
||
Latest revision as of 18:27, 2 March 2022
 | |
| Clinical data | |
|---|---|
| Other names | 5,6-Dihydro-2-methyl-4-[4-nitro-3-(trifluoromethyl)phenyl]-2H-1,2,4-oxadiazin-3-(4H)-one[1] |
| Drug class | Nonsteroidal antiandrogen |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H10F3N3O4 |
| Molar mass | 305.213 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
RU-22930 is a nonsteroidal antiandrogen (NSAA) related to the NSAAs flutamide and nilutamide (RU-23908) and was developed by Roussel Uclaf but was never marketed.[2][3] It is a selective antagonist of the androgen receptor and consequently has progonadotropic effects by increasing gonadotropin and testosterone levels via disinhibition of the hypothalamic-pituitary-gonadal axis.[2] Unlike flutamide and nilutamide, the drug is said to be short-acting and inactive by injection, but it has been found to be active topically in animals, and hence could be useful for the treatment of androgen-dependent skin conditions.[2][4]
See also[edit]
References[edit]
- ^ "Compositions and methods for inhibiting the action of androgens".
- ^ a b c Tindall DJ, Chang CH, Lobl TJ, Cunningham GR (1984). "Androgen antagonists in androgen target tissues". Pharmacol. Ther. 24 (3): 367–400. doi:10.1016/0163-7258(84)90010-x. PMID 6205409.
- ^ Singh SM, Gauthier S, Labrie F (2000). "Androgen receptor antagonists (antiandrogens): structure-activity relationships". Curr. Med. Chem. 7 (2): 211–47. doi:10.2174/0929867003375371. PMID 10637363.
- ^ Thomson, D. S. (1989). "Pharmacology of Anti-androgens in the Skin". Pharmacology of the Skin II. Handbook of Experimental Pharmacology. Vol. 87 / 2. pp. 483–493. doi:10.1007/978-3-642-74054-1_36. ISBN 978-3-642-74056-5. ISSN 0171-2004.
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |